Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease (SESAD)
Investigator: Huntington Potter, PhD
Purpose: The purpose of this study is to learn if a drug called sargramostim is safe and if it can help improve thinking and memory in people with Alzheimer’s disease.
Timeline: The treatment part will last for 24 weeks
ClinicalTrials.gov Identifier: NCT04902703
Key Eligibility Criteria: You may be able to join the study if you are between 60 and 85 years old and have mild to moderate Alzheimer's disease. You must also have a study partner who can come to the scheduled visits, report any changes in your thinking and memory, and learn how to give daily shots of the study drug.
Diagnosis: Mild to Moderate Alzheimer's Disease
Participate
BALANCE-AAD-1: A Clinical Study for the Treatment of Agitation in Adults with Alzheimer's Disease
Investigator: Samantha Holden, MD
Purpose: This study is testing an oral study drug to see if it can safely treat agitation in adults with Alzheimer’s disease.
Timeline: Participants may be in the study for up to 5.5 months
ClinicalTrials.gov Identifier: NCT06808984
Key Eligibility Criteria: Are 55 to 90 years of age. Have Alzheimer’s disease. Have been experiencing agitation for at least 4 weeks.
Diagnosis: Agitation in Alzheimer's Disease
Participate
